This report was first published by Endpoints News. To see the original version, click here
Kailera Therapeutics, one of the most closely-watched private obesity biotechs, has raised a $600 million Series B to begin Phase 3 trials by year’s end.
The Tuesday morning financing is the same size as Isomorphic Labs’ capital haul in March, tying Kailera with the Alphabet AI drug discovery unit for the largest biotech fundraise of the year.
您已閱讀16%（434字），剩余84%（2298字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。